Logo image of CRL

CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis

NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD

149.79  -4.69 (-3.04%)

After market: 160.1 +10.31 (+6.88%)

Fundamental Rating

4

Overall CRL gets a fundamental rating of 4 out of 10. We evaluated CRL against 54 industry peers in the Life Sciences Tools & Services industry. CRL has only an average score on both its financial health and profitability. CRL is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

CRL had positive earnings in the past year.
In the past year CRL had a positive cash flow from operations.
CRL had positive earnings in each of the past 5 years.
Each year in the past 5 years CRL had a positive operating cash flow.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

1.2 Ratios

The Return On Assets of CRL (-0.42%) is better than 66.67% of its industry peers.
The Return On Equity of CRL (-0.99%) is better than 68.52% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.12%, CRL is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CRL is significantly below the industry average of 13.60%.
Industry RankSector Rank
ROA -0.42%
ROE -0.99%
ROIC 6.12%
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

In the last couple of years the Profit Margin of CRL has declined.
CRL's Operating Margin of 12.59% is fine compared to the rest of the industry. CRL outperforms 72.22% of its industry peers.
CRL's Operating Margin has been stable in the last couple of years.
CRL's Gross Margin of 34.69% is on the low side compared to the rest of the industry. CRL is outperformed by 62.96% of its industry peers.
CRL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.59%
PM (TTM) N/A
GM 34.69%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
Compared to 1 year ago, CRL has less shares outstanding
Compared to 5 years ago, CRL has more shares outstanding
The debt/assets ratio for CRL has been reduced compared to a year ago.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

An Altman-Z score of 2.20 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
CRL has a Altman-Z score (2.20) which is comparable to the rest of the industry.
The Debt to FCF ratio of CRL is 4.46, which is a neutral value as it means it would take CRL, 4.46 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.46, CRL is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
CRL has a Debt/Equity ratio of 0.79. This is a neutral value indicating CRL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.79, CRL is not doing good in the industry: 75.93% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 4.46
Altman-Z 2.2
ROIC/WACC0.61
WACC10.08%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

CRL has a Current Ratio of 1.43. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.43, CRL is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
CRL has a Quick Ratio of 1.16. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
CRL has a Quick ratio of 1.16. This is in the lower half of the industry: CRL underperforms 77.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.16
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

4

3. Growth

3.1 Past

CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.47%.
The Earnings Per Share has been growing by 8.93% on average over the past years. This is quite good.
CRL shows a decrease in Revenue. In the last year, the revenue decreased by -2.16%.
Measured over the past years, CRL shows a quite strong growth in Revenue. The Revenue has been growing by 9.09% on average per year.
EPS 1Y (TTM)2.47%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%3.08%
Revenue 1Y (TTM)-2.16%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-2.71%

3.2 Future

Based on estimates for the next years, CRL will show a small growth in Earnings Per Share. The EPS will grow by 5.19% on average per year.
Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-6.05%
EPS Next 2Y0.2%
EPS Next 3Y3.14%
EPS Next 5Y5.19%
Revenue Next Year-3.29%
Revenue Next 2Y-0.44%
Revenue Next 3Y1.38%
Revenue Next 5Y1.71%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 5 10 15 20 25

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 14.42, the valuation of CRL can be described as correct.
Based on the Price/Earnings ratio, CRL is valued cheaply inside the industry as 92.59% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.46. CRL is valued slightly cheaper when compared to this.
CRL is valuated correctly with a Price/Forward Earnings ratio of 14.46.
CRL's Price/Forward Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 87.04% of the companies in the same industry.
CRL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.44.
Industry RankSector Rank
PE 14.42
Fwd PE 14.46
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 96.30% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CRL is valued cheaper than 90.74% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.06
EV/EBITDA 10.93
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.62
EPS Next 2Y0.2%
EPS Next 3Y3.14%

More info and screens

0

5. Dividend

5.1 Amount

CRL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHARLES RIVER LABORATORIES

NYSE:CRL (7/21/2025, 8:04:00 PM)

After market: 160.1 +10.31 (+6.88%)

149.79

-4.69 (-3.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners110.99%
Inst Owner Change-0.87%
Ins Owners0.9%
Ins Owner Change8.66%
Market Cap7.36B
Analysts66.09
Price Target160.61 (7.22%)
Short Float %4.93%
Short Ratio2.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.73%
Min EPS beat(2)4.03%
Max EPS beat(2)11.44%
EPS beat(4)4
Avg EPS beat(4)9.24%
Min EPS beat(4)4.03%
Max EPS beat(4)15.8%
EPS beat(8)8
Avg EPS beat(8)7.7%
EPS beat(12)12
Avg EPS beat(12)6.68%
EPS beat(16)16
Avg EPS beat(16)5.87%
Revenue beat(2)2
Avg Revenue beat(2)2.18%
Min Revenue beat(2)0.91%
Max Revenue beat(2)3.45%
Revenue beat(4)3
Avg Revenue beat(4)1.48%
Min Revenue beat(4)-0.86%
Max Revenue beat(4)3.45%
Revenue beat(8)6
Avg Revenue beat(8)1.16%
Revenue beat(12)9
Avg Revenue beat(12)1.3%
Revenue beat(16)11
Avg Revenue beat(16)1.06%
PT rev (1m)0.04%
PT rev (3m)-11.04%
EPS NQ rev (1m)-0.1%
EPS NQ rev (3m)5.52%
EPS NY rev (1m)0.04%
EPS NY rev (3m)2.92%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)2.74%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)2.05%
Valuation
Industry RankSector Rank
PE 14.42
Fwd PE 14.46
P/S 1.83
P/FCF 13.06
P/OCF 9.48
P/B 2.3
P/tB N/A
EV/EBITDA 10.93
EPS(TTM)10.39
EY6.94%
EPS(NY)10.36
Fwd EY6.92%
FCF(TTM)11.47
FCFY7.66%
OCF(TTM)15.81
OCFY10.55%
SpS81.89
BVpS65.03
TBVpS-6.82
PEG (NY)N/A
PEG (5Y)1.62
Profitability
Industry RankSector Rank
ROA -0.42%
ROE -0.99%
ROCE 7.75%
ROIC 6.12%
ROICexc 6.35%
ROICexgc 14.43%
OM 12.59%
PM (TTM) N/A
GM 34.69%
FCFM 14%
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexcg growth 3Y-14.69%
ROICexcg growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 4.46
Debt/EBITDA 2.78
Cap/Depr 53.72%
Cap/Sales 5.3%
Interest Coverage 4.43
Cash Conversion 85.97%
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 1.16
Altman-Z 2.2
F-Score4
WACC10.08%
ROIC/WACC0.61
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)2.47%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%3.08%
EPS Next Y-6.05%
EPS Next 2Y0.2%
EPS Next 3Y3.14%
EPS Next 5Y5.19%
Revenue 1Y (TTM)-2.16%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-2.71%
Revenue Next Year-3.29%
Revenue Next 2Y-0.44%
Revenue Next 3Y1.38%
Revenue Next 5Y1.71%
EBIT growth 1Y-19.26%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year30.58%
EBIT Next 3Y13.83%
EBIT Next 5Y8.72%
FCF growth 1Y104.63%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y23.95%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%